RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

August 31, 2013

Conditions
OverweightObesity
Interventions
DRUG

orlistat 60 mg

"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."

DEVICE

polyglucosamine

"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."

Trial Locations (2)

63303

Diabetological Center, Dreieich

87036

MAP Center, Rende

Sponsors
All Listed Sponsors
lead

Certmedica International GmbH

INDUSTRY

NCT02529631 - RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity | Biotech Hunter | Biotech Hunter